U.S. markets closed

Ambrx Biopharma Inc. (AMAM)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
13.77+0.46 (+3.46%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close13.31
Open13.45
Bid10.19 x 1400
Ask14.03 x 3000
Day's Range13.45 - 14.17
52 Week Range13.01 - 22.87
Volume21,705
Avg. Volume31,825
Market Cap518.709M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.00
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est53.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Ambrx Biopharma Inc.
    Analyst Report: Salesforce.com IncSalesforce.com is a cloud-based software-as-a-service customer relationship management or CRM software company. It offers its software through its Sales Cloud, Service Cloud, Marketing Cloud, and Salesforce Platform solutions. The company has expanded its offerings into the mobile, social networking, analytics, and artificial intelligence areas. Salesforce.com sells its software on a subscription basis, both directly and through third-party partners, including systems integrators, consulting firms, and distributors. About 32% of Salesforce.com's revenue comes from outside the U.S. The company was founded in 1999 and went public in June 2004.
    Rating
    Fair Value
    Economic Moat
    29 days agoArgus Research
View more